v3.26.1
Business Segment Information
 9 Months Ended
Jul. 31, 2026
Segment Reporting [Abstract]  
Business Segment Information
Note 10. Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that our Chief Operating Decision Maker (CODM) organizes segments within the Company for making operating decisions and assessing financial performance. Our CODM is our Chief Executive Officer. The Company's two operating segments are described below.
•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.
•CooperSurgical. Competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.
The CODM uses operating income, as presented in our financial reports, as the primary measure of segment profitability to assess the performance of the segments and make decisions on resource allocation across segments. The CODM evaluates segment operating income on a quarterly basis by comparing actual results to forecasted amounts and historical performance. These evaluations, supported by discussions with the leadership team responsible for managing the operations of each reportable segment, are used to assess segment results, monitor operating trends, and support decisions regarding the allocation of resources and consideration of investment opportunities. The Company does not allocate costs from corporate functions to segment operating income. The Company uses the same accounting policies to generate segment results as it does for consolidated results.
The following tables present revenue and other financial information by reportable segment:
Segment information:
Periods Ended July 31,Three MonthsNine Months
(In millions)2026202520262025
CooperVision net sales by category:
Toric and multifocal$363.8 $358.8 $1,079.9 $1,006.6 
Sphere, other353.2 359.6 1,055.7 1,027.5 
Total CooperVision net sales$717.0 $718.4 $2,135.6 $2,034.1 
CooperSurgical net sales by category:
Office and surgical$208.0 $204.8 $624.6 $609.5 
Fertility141.2 137.1 411.6 383.7 
Total CooperSurgical net sales349.2 341.9 1,036.2 993.2 
Total net sales$1,066.2 $1,060.3 $3,171.8 $3,027.3 
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
Three Months Ended July 31, 2026
Net sales$717.0 $349.2 $— $1,066.2 
Cost of sales240.4 113.9 — 354.3 
Selling, general and administrative expense244.6 132.1 24.6 401.3 
Research and development expense22.3 19.3 — 41.6 
Amortization of intangibles4.2 42.8 — 47.0 
Operating income (loss)$205.5 $41.1 $(24.6)$222.0 
Interest expense21.5 
Other (income) expense, net
(1.3)
Income before income taxes
$201.8 
Depreciation expense$40.9 $6.7 $— $47.6 
Capital expenditures$60.4 $8.3 $— $68.7 
As of July 31, 2026
Identifiable assets$7,915.1 $4,542.7 $215.6 $12,673.4 
Three Months Ended July 31, 2025
Net sales$718.4 $341.9 $— $1,060.3 
Cost of sales238.3 130.0 — 368.3 
Selling, general and administrative expense248.1 150.9 22.7 421.7 
Research and development expense24.3 20.3 — 44.6 
Amortization of intangibles5.1 44.9 — 50.0 
Operating income (loss)$202.6 $(4.2)$(22.7)$175.7 
Interest expense25.4 
Other (income) expense, net(1.6)
Income before income taxes$151.9 
Depreciation expense$39.0 $6.7 $— $45.7 
Capital expenditures$86.4 $10.5 $— $96.9 
As of October 31, 2025
Identifiable assets$7,604.4 $4,619.3 $171.1 $12,394.8 
(1) Corporate selling, general and administrative (SGA) expense is not allocated to the segments.
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
Nine Months Ended July 31, 2026
Net sales$2,135.6 $1,036.2 $— $3,171.8 
Cost of sales690.6 338.7 — 1,029.3 
Selling, general and administrative expense734.4 662.9 70.4 1,467.7 
Research and development expense66.8 61.6 — 128.4 
Amortization of intangibles12.5 130.1 — 142.6 
Operating income (loss)$631.3 $(157.1)$(70.4)$403.8 
Interest expense64.8 
Other (income) expense, net
(6.6)
Income before income taxes
$345.6 
Depreciation expense$123.3 $19.7 $— $143.0 
Capital expenditures$231.2 $26.1 $— $257.3 
Nine Months Ended July 31, 2025
Net sales$2,034.1 $993.2 $— $3,027.3 
Cost of sales658.9 337.1 — 996.0 
Selling, general and administrative expense714.9 423.6 70.1 1,208.6 
Research and development expense72.4 58.4 — 130.8 
Amortization of intangibles15.0 134.4 — 149.4 
Operating income (loss)$572.9 $39.7 $(70.1)$542.5 
Interest expense75.6 
Other (income) expense, net
17.2 
Income before income taxes$449.7 
Depreciation expense$111.4 $18.7 $— $130.1 
Capital expenditures$231.4 $33.0 $— $264.4 
(1) Corporate SGA expense is not allocated to the segments.
Geographic information:
Periods Ended July 31,Three MonthsNine Months
(In millions)2026202520262025
Net sales to unaffiliated customers by country of domicile:
United States$519.5 $516.2 $1,581.2 $1,527.8 
Europe357.5 343.1 1,025.5 922.5 
Rest of world189.2 201.0 565.1 577.0 
Total$1,066.2 $1,060.3 $3,171.8 $3,027.3 
(In millions)July 31, 2026October 31, 2025
Net property, plant and equipment by country of domicile:
United States$1,439.1 $1,389.4 
Europe452.6 429.1 
Rest of world253.2 263.5 
Total$2,144.9 $2,082.0